A COST - COMPARISON OF THE USE OF INFLUENZA VACCINE IN OLD AGE HOME RESIDENTS IN JOHANNESBURG by Cobb, Hugh
  
A COST - COMPARISON OF THE USE OF INFLUENZA 
VACCINE IN OLD AGE HOME RESIDENTS IN 
JOHANNESBURG 
 
 
 
 
 
Hugh Cobb 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A research report submitted to the Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, in partial fulfilment of the requirements for 
the degree of Master of Family Medicine 
 
ii
Declaration 
 
 
I, Dr. Hugh Cobb, declare that this research report is my own work. It is being 
submitted in partial fulfilment for the degree of Master of Family Medicine in the 
University of the Witwatersrand, Johannesburg. It has not been submitted before 
for any degree or examination at this or any other university. 
 
 
This study has received ethical clearance from the University of the 
Witwatersrand’s Committee for Research on Human Subjects (Medical) and the 
clearance certificate number is: M01-05-35 
 
 
 
 
 
 
 
Dr. Hugh Cobb 
 
 
October 2004 
 
 
 
 
 
 
iii
Abstract 
 
Residents of old age homes are at increased risk for the complications of 
influenza. Studies in developed countries have consistently shown that influenza 
vaccination of old age home residents and staff can significantly decrease 
morbidity and mortality rates and that influenza vaccination is one of the most cost 
effective interventions possible in this population. No studies have been done on 
the cost benefit of using influenza vaccine in old age home residents in South 
Africa. The aim of this study was to evaluate the costs of treating influenza and 
influenza-like illnesses in old age home residents, and to compare the costs in 
people who had received the influenza vaccine to those who had not. 
 
The study population comprised 151 people residing in two old age homes in 
Johannesburg, namely Sandringham Gardens and Nazareth House. The study 
population was divided into two groups- those who received influenza vaccine and 
those who had not been vaccinated. The residents of Nazareth House who gave 
consent had all been vaccinated. The subjects at Sandringham Gardens were 
sub- divided into two groups, namely: “Residents” and “Frail care / wards” section. 
The general health of the “Frail care” people was poorer than that of the 
“residents”. 
 
Medical records were reviewed, and details of the number of doctor consultations, 
medication and physiotherapy prescribed, special investigations performed and 
hospital referrals related to influenza and influenza-like infections were recorded. 
The costs were then calculated using “medical aid rates”. There were no 
significant differences in the treatment costs, comparing those who had been 
vaccinated to those who had not been vaccinated. There are a number of possible 
explanations for this. These include, most importantly, a low to moderate epidemic 
activity of influenza in the season that the study was conducted. Other 
explanations are low patient numbers, the use of symptoms for diagnosis and the 
use of over the counter therapy. 
 
iv
Despite the findings in the present study, the international literature supports the 
view that influenza vaccination is a cost-effective intervention in the older adult 
population, particularly those at higher risk. These findings have been 
implemented in the official guidelines of many countries, including the South 
African Adult Influenza Vaccination Guideline. 
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CHAPTER 1 
Introduction 
 
1.1. Background 
 
Influenza is an important acute respiratory infection that causes significant 
preventable morbidity and mortality. Influenza viruses cause disease among all 
age groups. Rates of infection have been reported to be highest among children, 
but rates of serious illness and death are highest among persons aged >65 years 
and in persons of any age who have medical conditions that place them at 
increased risk for complications from influenza.1 Old age home residents and 
others living in closed communities are more likely to be infected, because virus 
transmission is facilitated by living in close proximity.2 This is shown in table 1: 
 
Table 1.1: Incidence of clinical influenza in various studies from the USA2 
 
a) General Population 
 
 
b) Closed Environments 
Population Rate (%) 
Nursing homes 43-60 
US military bases 30-87 
Families of infected individuals 10 
 
Influenza can produce repeated infections throughout life, is highly communicable, 
and is responsible for annual community epidemics of varying severity. In addition 
Population Rate (%) 
children 37 
people aged > 20 years 4-15 
elderly (aged > 60 years) 10 
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to its acute respiratory presentation, influenza is also a systemic infection that 
predisposes particularly to pulmonary and cardiac complications.3 
 
1.2. Molecular Epidemiology of Influenza 
 
“Influenza viruses are members of the Orthomyxoviridae family. The designation of 
influenza viruses as type A, B, or C is based on antigenic characteristics of the 
nucleoprotein (NP) and matrix (M) protein antigens.  
 
Influenza A viruses are further subdivided (subtyped) on the basis of the surface 
haemagglutinin (H) and neuraminidase (N) antigens; individual strains are 
designated according to the site of origin, isolate number, year of isolation, and 
subtype-for example, influenza A/Sydney/5/97 (H3N2).  
 
Influenza B and C viruses are similarly designated, but H and N antigens from 
these viruses do not receive subtype designations, since intratypic variations in 
influenza B antigens are less extensive than those in influenza A viruses and may 
not occur with influenza C virus.”4 
 
Influenza A has 2 subtypes which are important for humans: A (H3N2) and  
A (H1N1), of which A (H3N2) is currently associated with most deaths.5 Influenza 
C virus infection does not cause classic influenza illness.6 Wild birds are 
considered  the natural hosts for influenza A virus and the influenza viruses that 
infect birds are called “avian influenza viruses”. These viruses do not usually 
directly infect or circulate among humans, however there have been several 
reports of human infections with avian influenza A since 1997.7 Avian influenza A 
(H5N1) is commonly known as “bird flu”. Influenza A (H5N1) was first isolated from 
terns, which are aquatic birds, in South Africa in 1961.8 
 
An influenza pandemic is caused by antigenic shift of influenza A resulting in the 
appearance of an influenza virus with a novel haemagglutinin (H antigen), together 
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with or without a novel neuraminidase (N antigen) subtype. There have been three 
global pandemics of influenza in the 20th century.7 “Experts agree that another 
influenza pandemic is inevitable and possibly imminent.”9  
 
Immunity to these antigens, especially the haemagglutinin, reduces the chance of 
infection as well as the severity of the infection if it does occur. Both influenza A 
and B undergo antigenic variation. The antigenic characteristics of the currently 
circulating strains provide the basis for selecting the virus strains to be included in 
each year’s vaccine,10 and therefore monitoring the antigenicity of viruses 
circulating each year is necessary to ensure the best possible match between the 
prevailing viruses and the vaccine strains.  
 
During interpandemic periods, outbreaks of influenza A or B infection are reported 
nearly every winter and vary in severity. Antigenic variability during interpandemic 
periods is less marked and is caused by antigenic drift. This describes a process 
of minor antigenic changes resulting from the accumulation of random point 
mutations. These mutations lead to alterations in the amino acid composition of 
haemagglutinin and neuraminidase. New strains of influenza A and B are 
constantly being generated by antigenic drift, and epidemics arise if circulating 
strains are significantly different from previous strains encountered by the 
population.11 
 
1.3. Symptoms of Influenza 
 
Influenza is characterized by sudden onset of high fever, myalgia, headache and 
severe malaise, non-productive cough, sore throat, and rhinitis. Most people 
recover within one to two weeks without requiring any medical treatment. In the 
very young, the elderly and people suffering from medical conditions such as lung 
diseases, diabetes mellitus, carcinoma and renal or cardiac failure, influenza 
poses a serious risk. In these people, the infection may lead to severe 
complications of underlying diseases, pneumonia and death.5 
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Influenza can resemble numerous other acute winter respiratory infections, all 
casually referred to as the “flu”. As a consequence, its potential severity often goes 
unappreciated by the lay population and even some doctors. This lack of 
awareness of its potential to produce serious disease is a barrier to implementing 
a successful vaccination program.3 
 
 
1.4. Control of Influenza 
 
The occurrence and impact of influenza can be reduced by immunoprophylaxis 
with inactivated (killed) virus vaccine and chemoprophylaxis with influenza specific 
antiviral drugs.10 
 
Vaccination is the principal measure for preventing influenza and reducing the 
impact of epidemics. Various types of influenza vaccines have been available and 
used for more than 60 years. They are safe and effective in preventing both mild 
and severe outcomes of influenza. Constant genetic changes in influenza viruses 
mean that the vaccines' virus composition must be adjusted annually to include the 
most recent circulating influenza A (H3N2), A (H1N1) and influenza B viruses.5  
 
There is evidence that widespread use of influenza vaccine can produce what has 
been proposed as “herd immunity” that limits the spread of viruses during 
influenza epidemics.3 
 
Antiviral drugs for influenza are an adjunct to influenza vaccine for the treatment 
and prevention of influenza in certain circumstances. However, they are not a 
substitute for vaccination. There are four antiviral drugs that act by preventing 
influenza virus replication. For several years, amantadine and rimantadine (not 
available in South Africa) were the only antiviral drugs. However, whilst relatively 
inexpensive, these drugs are effective only against type A influenza, and may be 
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associated with severe adverse effects, mostly in elderly persons on higher doses. 
In addition, the virus tends to develop resistance to these drugs. 
 
A new class of antivirals, the neuraminidase inhibitors, has been developed. Such 
drugs, including zanamivir (which is available in South Africa) and oseltamivir, 
have fewer adverse side effects and the virus less often develops resistance to 
these drugs. However, these drugs are expensive and currently not available for 
use in many countries.5 
 
The major goal of the influenza vaccine policy is to protect individuals from 
complications of influenza. Many of the highest risk individuals are at the end of 
the transmission chain, and therefore immunization of these groups cannot be 
expected to alter the course of an epidemic.3 
 
Influenza remains a major cause of morbidity and mortality, especially in the 
geriatric population. While influenza vaccination is a low cost and effective method 
of preventing illness and reducing productivity losses, its level of use in society has 
been too low to achieve more than a small portion of its potential benefit.12 South 
Africa as a country is well behind the developed world in its usage of influenza 
vaccine13 and there is in South Africa a pervasive apathy and lack of awareness of 
the benefits of influenza vaccination compared with developed countries.14 
 
 
1.5. The economic cost of Influenza 
 
Influenza epidemics and pandemics have a huge impact on both society and 
individual sufferers. Scarce resources and increasing medical costs highlight the 
need to quantify the burden of diseases such as influenza and subsequently to 
make accurate economic assessments of the available interventions. 
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Direct costs relating to hospitalisation and treatment are greater for high-risk 
patient groups. In general, the highest hospitalisation rates occur in infants (<1 
year old) and the elderly, with pneumonia being the major reason for 
hospitalisation.2 
 
Only a limited amount of information is available regarding the economic benefits 
of influenza vaccination of the elderly in South Africa. This research work will 
hopefully begin filling the void. The South African studies that have been 
undertaken were performed in an occupational and general population setting, and 
did not determine the cost-effectiveness of influenza vaccination in the elderly, or 
in those with chronic illness or other high risk groups.15, 16  
 
 
1.6. Aim and Objectives 
 
The aim of this study was to evaluate the costs of treating influenza and influenza- 
like illnesses in old age home residents in Johannesburg, comparing people who 
received the influenza vaccine with those who had not. 
 
The objectives of the study were to: 
a. Describe the demographic profile of the subjects in terms of age and 
gender 
b. Record existing co-morbid medical conditions 
c. Record which subjects were vaccinated for influenza 
d. Record the number of influenza and influenza- like illnesses during one 
Winter season 
e. Record direct medical resources consumed: 
• Number of doctors’ visits  
• Type and number of laboratory tests and chest radiographs 
  performed 
• Types and amount of medications consumed 
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• Amount of chest physiotherapy used 
• Hospitalisation and length of stay 
f. Calculate the costs of medical resources consumed, and comparing the 
costs of those who were vaccinated for influenza with those who were not. 
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CHAPTER 2 
Literature Review 
 
2.1. Overview 
Although only a small portion of older individuals live in old age homes, much of 
the literature on influenza in this age group describes outbreaks in such facilities. 
Old age home residents are uniquely vulnerable to influenza morbidity and 
mortality. Although independently living older persons actually experience 
relatively low rates of clinical influenza compared with younger persons, this is not 
always true in the elderly residing in old age homes. Once introduced into a 
facility, usually by staff or visitors, influenza can spread rapidly because of close 
contact among residents and because of their overall health status. The latter 
element is clearly involved in the severe manifestations of influenza illness, which 
can cause serious medical complications or death.17 
 
Concerns about the safety, efficacy and cost-effectiveness of influenza vaccination 
have resulted in it being underutilised. The vaccine has been shown to be highly 
effective in preventing infections in young healthy individuals, but because of 
availability and cost considerations, most international recommendations and the 
South African Guidelines10 for vaccine use target the elderly and certain other 
groups of patients who are at increased risk of acquiring influenza and its 
complications.17 
 
 
2.2. Influenza Vaccine Effectiveness in the Elderly 
 
Vaccine effectiveness is one of the crucial parameters in the economic evaluation 
of influenza vaccination in the elderly. If an estimate of effectiveness comes from a 
controlled clinical trial, it is actually efficacy that is being measured. Most of the 
literature being reviewed assumes that effectiveness equals efficacy. 
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The effectiveness of the influenza vaccine can be assessed in terms of: 
a. Prevention of influenza-like illness in healthy adults younger than 65 years 
or in nursing home residents older than 65 years. 
b. Prevention of hospitalisation because of pneumonia. 
c. Prevention of death in the elderly.  
d. Reduction of other negative consequences such as work or school 
absenteeism, visits to doctors' offices because of upper respiratory 
diseases, and so on. 
 
Studies in students, military recruits, healthy working adults, and health care 
workers have established a vaccine efficacy of about 70% to 90% in reducing 
cases of influenza and laboratory-confirmed illness, principally during years when 
there is a good antigenic match between vaccine and circulating strains. When 
there was a poor match, the vaccine efficacy was 40% to 60%.18 
 
Questions have been raised about the effectiveness of influenza vaccination in the 
elderly, because influenza outbreaks occur even in nursing homes with high rates 
of vaccination, in years when there is little difference between the circulating strain 
and the vaccine.18 
 
A cohort study of influenza vaccine effectiveness among elderly nursing home 
residents was published by Monto, et al, in 2001.17 The study population were 
residents aged 65 years and older, living in participating nursing homes. The 
eligible population numbered 2 351 residents. 
 
 Influenza vaccine was found to be: 
• 35% effective in preventing total respiratory illness (influenza- like illness 
and clinically diagnosed pneumonia), 
• 55% effective in preventing pneumonia alone.  
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A clinical definition of influenza was used in this study, although additional data on 
influenza virus activity was generated from virus isolation from throat cultures. 
 
Nichol et al19 evaluated the benefits of influenza vaccination in the elderly, 
comparing these benefits in three subgroups of people, as defined by co-morbid 
medical conditions. In this cohort study, subjects were grouped according to risk 
status: high risk (having heart or lung disease), intermediate risk (having diabetes 
mellitus, renal disease, stroke and/or dementia, or rheumatologic disease), and 
low risk. 
 
Vaccination was associated with an overall reduction of: 
• 39% for pneumonia hospitalisation  
• 32% decrease in hospitalisations for all respiratory conditions  
• 27% decrease in hospitalisations for congestive heart failure  
Vaccination was also associated with a 50% reduction in all-cause mortality. 
 
Within the risk subgroups, vaccine effectiveness was 29%, 32%, and 49% 
respectively for high-, intermediate-, and low-risk senior citizens for reducing 
hospitalisations for pneumonia and influenza. Effectiveness was 19%, 39%, and 
33% respectively, for reducing hospitalisations for all respiratory conditions and 
49%, 64%, and 55% respectively for reducing deaths from all causes. This study 
concluded that healthy senior citizens as well as senior citizens with underlying 
medical conditions are at risk for the serious complications of influenza and benefit 
from vaccination.  
 
Drinka et al 20 demonstrated that large outbreaks of influenza may occur in old age 
homes, despite high resident vaccination rates, even when the vaccine strain is 
matched to the circulating strain. In this study, 85% of residents were vaccinated. 
Prospective surveillance was carried out, and cultures were performed even on 
those with mild symptoms. 
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Two seasons were studied, and both outbreaks were associated with non-
significant increases in pneumonia and influenza mortality. The authors comment 
that although vaccination may not prevent illness, it can reduce the severity of 
illness and complications. 
 
To quantify the protective efficacy of influenza vaccine in elderly persons, Gross 
and colleagues21 did a meta-analysis on 20 observational studies, all except one 
consisting of institutionalised elderly. Only cohort observational studies with 
mortality assessment were included in the meta-analysis. In addition, 3 case-
control studies, 2 cost-effectiveness studies, and 1 randomised, double-blind, 
placebo-controlled trial were reviewed.  
 
The pooled estimates of vaccine efficacy were: 
• 56% for preventing respiratory illness 
• 53% for preventing pneumonia, 
• 50% for preventing hospitalisation 
• 68% for preventing death 
 
Vaccine efficacy in the case-control studies ranged from: 
• 32% to 45% for preventing hospitalisation for pneumonia 
• 31% to 65% for preventing hospital deaths from pneumonia and influenza 
• 43% to 50% for preventing hospital deaths from all respiratory conditions 
• 27% to 30% for preventing deaths from all causes.  
 
The randomised, double-blind, placebo-controlled trial showed a 50% or greater 
reduction in influenza-related illness. The authors of this meta-analysis and review 
make an important comment: “Studies on vaccine efficacy, therefore, need to be 
evaluated with caution. Standard definitions for influenza-like illness, influenza-
related pneumonia, hospitalization, and death do not exist, and this confounds 
comparisons among studies”. 
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2.3. Pharmacoeconomics of influenza vaccination in the elderly and in the 
general population 
 
As expenditure in healthcare increases, interest in the efficiency of certain 
interventions in healthcare has also increased. South Africa is one of many 
countries trying to balance the seemingly unlimited demand for health care with 
limited resources. From a pharmacoeconomic point of view, it is relevant to 
consider whether influenza vaccination in the elderly is worthwhile, namely, 
whether the benefits of vaccination surpass the costs, or if not, whether the net 
investment “buys sufficient health gains”.22 
 
No data on the pharmacoeconomics of vaccination in the elderly in South Africa 
are available. A study by Schoub and Martin15 had two arms, an occupational 
setting and the general population. In the occupational study (ESKOM study), it 
was found that the benefit: cost ratio (BCR) was 5:1. The benefits were those of 
reduced absenteeism, as well as reduced medical costs. This was assuming that 
the vaccine was 43% effective in reducing absenteeism, and that there was 100% 
vaccination rate. The population (medical aid study) found that in 1995, if all 
people with access to medical aid had been vaccinated, and assuming an 80% 
vaccine efficacy, the medical aid industry would have saved approximately R53 
million rand. A clinical diagnosis of influenza was used, and for other respiratory 
illnesses, a proportion of 25% was assumed to be influenza related. 
 
A retrospective study by Boorman,16 of about 700 manufacturing industry 
employees, found that the non- vaccinated group were twice as likely to be off 
work for illness compatible with influenza, compared with employees who were 
vaccinated. This study also used clinical diagnoses, but included other respiratory 
infections, such as sinusitis, as surrogate markers of influenza. 
 
A review of the available evidence related to the pharmacoeconomics of 
vaccination in the elderly was published by Postma and his colleagues.22 Their 
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selection criteria included studies published between 1980 and 1999, and 
excluded cost-of-illness and burden-of-illness assessments, such as this study. Of 
the ten studies that were selected, 6 refer to the USA, 2 to the Netherlands, 1 to 
Canada and 1 to New Zealand. None of the studies took place in a developing 
country. The subjects were not institutionalised, except for one study. Four studies 
found benefit: cost ratios of 5 or more, three studies found benefit: cost ratios 
ranging from 1.5 to 5, and 3 studies found benefit: cost ratios ranging from 0.7 to 
1.2. In all these studies, only direct costs were measured. This was justified on the 
basis that most elderly people would not be in paid jobs. 
 
Nichol and Goodman23 describe both health and economic benefits of influenza 
vaccination in the elderly. Data from 6 seasons was pooled. They examined claims 
from a managed healthcare organisation in the USA, and included both direct and 
indirect costs. They included indirect costs, because more than 40 % of all 
persons aged 65-74 years may have several types of unpaid jobs, such as 
housekeeping and taking care of children, which deserve monetary valuation. Two 
thirds of subjects were healthy, and one third was at increased risk of 
complications of influenza. They showed that the total net savings per person 
vaccinated was US $ 39.34 for healthy people and US$ 34.50 for at-risk people. 
 
In a population-based, case-control study,24 Mullooly et al showed that in an 
American Health Maintenance Organisation (HMO), the net savings to the HMO 
per vaccination was $6.11 for high-risk elderly persons and $1.10 for all elderly 
persons. The HMO incurred a net cost of $4.82 per vaccination for non-high-risk 
elderly persons. They concluded that the medical care costs saved by preventing 
pneumonia and influenza through vaccination of high-risk elderly persons provide 
compelling reasons to increase compliance with recommendations for annual 
influenza vaccination. Indirect benefits, such as prevention of suffering, incapacity, 
and lost wages, are likely to compensate for the small net cost of vaccinating non-
high-risk elderly persons. 
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2.4. Safety and Adverse Side Effects of Influenza Vaccination 
 
Several studies have shown that the vaccine lacks severe adverse effects.18 In 
placebo-controlled studies among adults, the most frequent side effect of 
vaccination is soreness at the vaccination site (affecting 10%–64% of patients) 
that lasts <2 days.1 These local reactions typically are mild and rarely interfere with 
the person's ability to conduct usual daily activities.  
 
Fever, malaise, myalgia, and other systemic symptoms can occur after vaccination 
and most often affect persons who have had no prior exposure to the influenza 
virus antigens in the vaccine (e.g., young children).1 These reactions begin 6–12 
hours after vaccination and can persist for 1–2 days. It has also been reported that 
“vaccine side-effects are more common in the elderly.”14 Acute, severe, 
anaphylactic reactions are rare.1 
 
 
2.5. Influenza vaccination in Developing Countries 
 
There are significant variations in influenza vaccination rates between different 
countries, despite similar vaccination guidelines.25 One important factor, is whether 
or not recipients have to pay for the vaccine themselves.26 
 
Van Essen et al25 summarised information on recommendations for influenza 
vaccination in 50 developed and rapidly developing countries, including South 
Africa in the year 2000. These countries included 2 in North America, 17 in 
western Europe, 11 in central Europe, 6 in the western Pacific, 7 in Latin America 
and 7 in the Middle East and Africa. Of the 50 countries reviewed, South Africa 
ranked 37 in the doses of influenza distributed per 1000 population, with a figure of 
43 doses/1000 population. The highest was in Canada, where 350 doses/1000 
population were distributed, and the lowest was Morocco, with 7 doses/1000 
population. 
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2.6. Summary of literature review 
 
Studies of influenza vaccine efficacy differ in their matching of virus strains and 
they are confounded by the presence of other respiratory pathogens that cause 
illness. Reasons for death are also difficult to determine, which further compounds 
the difficulty of attributing death to influenza. 
 
Appropriate laboratory studies should be done to fully characterize the causative 
infectious microorganisms responsible for an epidemic of respiratory illness. 
Without these determinations, attribution of morbidity and mortality may be 
imprecise. Vaccine efficacy, therefore, may be underestimated, and case-mortality 
rates in vaccinated persons are overestimated.  
 
Although it is not possible to make direct comparisons between studies of vaccine 
effectiveness because of the above limitations, annual influenza vaccination is 
effective in preventing influenza and its complications in old age home residents. 
There are also economic benefits associated with the routine annual vaccination of 
old age home residents.  
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CHAPTER 3 
Research Methods 
 
3.1 Methodology 
 
3.1.1. Design 
 
A cohort, observational study design was used 
 
3.1.2. Sites of Study 
 
The study was conducted at two old-age homes, Nazareth House (NH) and 
Sandringham Gardens (SG) in the North Eastern suburbs of Johannesburg. At the 
time of this study, the population of these homes were White, and can be 
classified as being from a middle income level. The two old age homes are similar, 
in that they are privately funded. 
 
It was planned to include two old age homes in Alexandra Township, where the 
residents of these homes at that time were Black, but it was not possible to obtain 
permission for this. These two homes are subsidised financially by the state, and 
the residents are from a lower income group. 
 
There are permanent full-time and part- time doctors at Sandringham Gardens and 
part time physiotherapists. There are no full time doctors or physiotherapists at 
Nazareth House.  
 
3.1.3. Study Population 
 
The target population was all the residents of Nazareth House and Sandringham 
Gardens. Consent to participate in the study was obtained for 298 of the 340 
residents at Sandringham Gardens. Accurate records of who received influenza 
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vaccine were available for only 117 subjects at Sandringham Gardens, of whom 
42 received influenza vaccine. Only these 117 people were included in the study. 
 
Nazareth House had 84 residents, of whom 34 gave informed consent to 
participate in the study. The response rate was 40 %. All of these 34 people had 
been vaccinated. The population who gave consent were ambulatory, and 
independent with regard to their activities of daily living. 
 
The population at Sandringham Gardens was subdivided into “residents” and 
“wards/ frail care”. The ward population were generally frailer, and the residents 
were ambulatory and more independent. The control group was the unvaccinated 
residents at both homes. Those not vaccinated were people who had contra-
indications to the vaccine and those who choose not to have it.  
 
3.1.4. Ethical Issues 
 
The researcher was known to the Medical Director of Sandringham Gardens and 
to the Matron at Nazareth House. The aim of the study was explained to them at 
the beginning of the year (2001) and their permission to use their facilities was 
requested. They were given the Case Report Form (CRF), shown in appendix B, 
and were given an opportunity to ask questions about the study, and suggest 
changes to the CRF. The confidentiality of the information gathered and anonymity 
was explained to them, and they were provided with informed consent forms to 
give to the subjects. They were requested to ask their staff, who were well known 
to the subjects, to obtain informed consent. The informed consent form is shown in 
Appendix A. 
 
No interference was made in the normal running of the old age homes. Informed 
consent was needed, as access to confidential medical records was required. For 
those people who could not give informed consent, for example, people with 
dementia, it was requested from those who have legal permission to give informed 
consent for the subjects. 
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Permission to conduct the study was obtained from the Committee for Research 
on Human Subjects, now called the Human Research Ethics Committee, of the 
University of the Witwatersrand. 
 
3.1.5. Data Collection 
 
In December 2001, all the medical records were reviewed by a final year medical 
student, and the information was recorded on a Case Report Form.  
The data recorded consisted of: 
a. Demographic information (Age, Gender) 
b. Vaccination history 
c. Presence or absence of co-morbid medical conditions 
d. Review of symptoms related to influenza and influenza-like illness (ILI) 
e. Review of interventions (including doctor consultations, hospital referral, 
special investigations, chest physiotherapy and nebulisations) 
f. Review of medications prescribed 
g. Details of hospitalisation (if relevant) 
 
3.1.6. Methods of Data Analysis 
 
The observations were captured onto spreadsheets (Microsoft Excel 2000, 
Microsoft Office), and then analysed using a statistics computer program, 
“GraphPad InStat” (GraphPad Software Inc, San Diego, CA, USA). Means and 
Standard deviations were used, and the unpaired t test was used to determine if 
differences were significant. Costs were calculated in Rands, using the “Medical 
Aid” rate. This is the amount that medical aids would pay for medical services, and 
is lower than the tariff recommended by the South African Medical Association. 
When costs differed for drugs as a result of package size (bulk packs versus 
standard), an average price was used. 
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CHAPTER 4 
Results 
 
4.1. Introduction 
 
The sample population consisted of a total of 151 subjects. 
These were made up of: 
a. Sandringham Gardens “Residents”: 85 
b. Sandringham Gardens “Wards”: 32 
c. Nazareth House: 34  
 
As the subjects in the wards at Sandringham Gardens had significantly higher 
costs, for both vaccinated and unvaccinated groups, than those ambulatory 
subjects (residents) at both Sandringham Gardens and Nazareth House, they 
were analysed as a separate group. 
 
 
4.2. Number of people vaccinated 
 
In total, 80 people (52%) were vaccinated. Less people were vaccinated in the 
Sandringham Gardens “Residents” category, compared to the “Wards”. This is 
shown in table 4.1. 
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Table 4.1: Number of people vaccinated 
(a) SG Residents (Total 85) 
Parameter Number 
Vaccinated 24 (28 %) 
Not Vaccinated 61 (72%) 
 
(b) SG Wards (Total 32) 
Parameter Number 
Vaccinated 18 (56%) 
Not Vaccinated 14 (44%) 
 
(c) NH Residents (Total 34) 
Parameter Number 
Vaccinated 34 (100%) 
 
 
4.3. Age distribution 
 
The mean ages of the subjects are shown in Table 4.2. As can be seen, the mean 
age for all groups was approximately 82 years and the average age for 
Sandringham Gardens Ward subjects was slightly lower. 
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Table 4.2: Mean ages of subjects 
 
 
 
 
 
 
 
 
 
 
 
 
 
The variation in the ages between the subgroups was not significantly different. 
 
 
4.4. Gender distribution 
 
As shown in Table 4.3, 33% of the Sandringham Gardens Residents were male, 
but all of the Sandringham Gardens Wards subjects were male. The reason for 
this is that accurate vaccination records were not kept for the females in the wards 
at Sandringham Gardens, and these females were therefore not included in this 
study. 
 
Parameter Mean age (years) SD  
SG Residents: 
Vaccinated (n=24) 
82.67 10.97 
SG Residents: 
Not Vaccinated (n=61) 
82.15 7.55 
NH  Residents:  
Vaccinated (n=34) 
82.06 15.87 
SG  Wards : 
Vaccinated (n=18) 
82.59 10.13 
SG  Wards :  
Not Vaccinated (n=14) 
79.80 9.65 
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Table 4.3: Gender distribution 
(a) SG Residents (n=85) 
Parameter Males (%) 
Vaccinated 33 
Not Vaccinated 67 
 
(b) SG Wards (n=32) 
Parameter Males (%) 
Vaccinated 32 (100) 
Not Vaccinated 0 
 
(c) NH Residents (n=34) 
Parameter Males (%) 
Vaccinated 21 (61.7) 
 
 
4.5. Co-morbid conditions 
 
In the tables below, lung disease includes chronic obstructive pulmonary disease 
and asthma. Diabetes mellitus includes non-insulin dependent diabetes and insulin 
dependent diabetes. The conditions reported under the heading “other” included a 
large number of conditions, such as arthritis and prostatism. 
 
Heart disease refers specifically to congestive cardiac failure. Neurological 
conditions include cerebrovascular accidents, Parkinson’s disease and dementia. 
Many subjects had more than one co-morbid condition. Information on the severity 
and degree of control of the co-morbid conditions was not available. 
 
In the Sandringham Gardens “residents” subgroup of subjects who were 
vaccinated, 26 out of 27 people had co-morbid conditions documented in their 
records (96.3 %). These are shown in table 4.4 (a) 
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Table 4.4: Co-morbid conditions 
(a) Sandringham Gardens – residents: vaccinated n=27 
Condition 
lung 
disease 
diabetes 
mellitus 
heart 
disease 
renal 
disease 
neurological 
disease 
other 
Number 4 3 8 0 2 26 
% 14.8 11.1 29.6 0 7.4 96.3 
 
In the Sandringham Gardens residents subgroup of subjects who were not 
vaccinated, all 61 people had co-morbid conditions documented in their records.  
 
(b) Sandringham Gardens – residents: not vaccinated n=61 
Condition 
lung 
disease 
diabetes 
mellitus 
heart 
disease 
renal 
disease 
neurological 
disease 
other 
Number  8 2 12 1 10 61 
% 13.1 3.2 19.6 1.63 16.39 100 
 
In the Sandringham Gardens wards subgroup of subjects who were vaccinated, all 
17 people had co-morbid conditions documented in their records.  
 
(c) Sandringham Gardens – wards: vaccinated n=17 
Condition 
lung 
disease 
diabetes 
mellitus 
heart 
disease 
renal 
disease 
neurological 
disease 
other 
Number 4 3 2 0 0 17 
% 23.5 17.6 11.7 0 0 100 
 
In the Sandringham Gardens wards subgroup of subjects who were not 
vaccinated, all 15 people had co-morbid conditions documented in their records.  
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(d) Sandringham Gardens – wards: not vaccinated n=15 
Condition 
lung 
disease 
diabetes 
mellitus 
heart 
disease 
renal 
disease 
neurological 
disease 
other 
Number 4 1 42 2 8 15 
% 26.6 6.6 26.6 13.3 53.3 100 
 
In the Nazareth House subgroup of subjects, all of whom were vaccinated, 14 out 
of 34 people had co-morbid conditions documented in their records.  
 
(e) Nazareth House: vaccinated n= 34 
Condition 
lung 
disease 
diabetes 
mellitus 
heart 
disease 
renal 
disease 
neurological 
disease 
other 
Number 4 2 4 0 2 34 
% 11.8 5.9 11.8 0 5.9 100 
 
 
4.6. Symptoms 
 
On the case report form (appendix B), 18 different symptoms related to influenza 
and influenza-like conditions were listed. Some of the symptoms recorded were 
specific, such as presence of a productive cough or sore throat, while others were 
less specific, such as fever or myalgia or a general deterioration in condition. At 
Nazareth House, a diagnosis was recorded with the monthly symptom review, but 
this was not done at Sandringham Gardens. At Sandringham Gardens, information 
on the diagnosis was available from the record of medications, where the 
indication for the medication was recorded.  
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At Nazareth House, the following diagnoses were made: 
a. Influenza - 8 episodes 
b. Bronchitis - 5 episodes 
c. Cold - 1 episode 
d. Lower respiratory tract infection - 1 episode 
e. Upper respiratory tract infection - 1 episode 
 
Some subjects had more than one episode of influenza or influenza like illness. 
Of all the subjects, one resident at Sandringham Gardens, who was not 
vaccinated, was admitted to hospital. No details regarding the duration of 
hospitalisation or treatment were available. 
 
The numbers of subjects having symptoms are shown in table 4.5. The 
Sandringham Gardens Wards group who were not vaccinated had lowest 
percentage of recorded symptoms, although there were only 7 subjects in this 
group. 
 
 
Table 4.5: Number of subjects having symptoms 
 
 
There was no significant difference between the number of Sandringham Gardens 
Residents in the vaccinated group who had symptoms, compared to the non-
vaccinated group. The two-tailed p value was 0.4821 
 
Group Number Percentage 
SG Residents: vaccinated ( 24) 15 62.5 % 
SG Residents: not vaccinated (61) 43 70.5 % 
SG Wards: vaccinated (18) 12 66.7 % 
SG Wards: not vaccinated  (14) 7 50.0 % 
NH: vaccinated (34) 16 47.1 % 
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There was no significant difference between the number of Sandringham Gardens 
Ward subjects in the vaccinated group who had symptoms, compared to the non- 
vaccinated group. The two-tailed p value was 0.3570 
 
 
4.7. Cost of interventions  
 
The following interventions were recorded, and the costs thereof calculated, in 
Rands: 
a. Doctors’ visits 
b. Radiographs 
c. Chest physiotherapy 
d. Blood tests 
e. Drugs 
 
Additional costs, in the form of increased nursing care needed, were not included. 
 
The costs were calculated using the “medical aid” for the year 2001. This is the fee 
that the Representative Association of Medical Aids (RAMS) pays a doctor for a 
consultation. The “private” rate is determined by the South African Medical 
Association, and is higher than the RAMS fee. The cost for a doctors’ visit was that 
of a consultation at a doctors offices, rather than for a house-call, because 
Sandringham Gardens has it’s own doctors, and at Nazareth House, it was not 
specified whether the doctor visited the site, or whether the patient went to the 
consulting rooms. 
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The costs used were: 
1. Doctors’ visit: R80.10 
2. Physiotherapy (Physio), per session: R115.00 (assumed to be 7 
sessions in 5 days) 
3. Radiographs ( CXR): R128.90 
d. Blood tests (Lab) 
i. Full Blood Count ( FBC) : R58.10 
ii. Erythrocyte Sedimentation Rate (ESR): R14.00 
iii. Urea and Electrolytes (U&E): R 90.70 
e. Drug costs. Calculated individually.  
 
The mean costs of medical intervention in the five subgroups are shown in table 
4.6. The costs were calculated as mean for the entire subgroup. For example, in 
the group of Sandringham Gardens Residents who were vaccinated, 15 out of 24 
subjects accounted for 22 doctors visits. The mean cost of doctors’ visits for the 15 
subjects was R117.48, and the mean cost calculated for the 24 subjects was 
R70.01. 
 
As shown in table 4.6, in all groups except Nazareth House subjects, the single 
most costly intervention was for drugs. 
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Table 4.6: Cost of Interventions  
Group Doctor CXR Physio Lab Drugs Total 
S G Residents 
vaccinated (24) 
R70.01 R10.78 R33.54 R6.20 R204.99 R328.16 
S G Residents not 
vaccinated (61) 
R65.66 R27.47 R0.00 R7.85 R228.99 R319.75 
SG–Wards: 
vaccinated (18) 
R66.75 R57.29 R0.00 R13.26 R732.06 R869.36 
SG–Wards not 
vaccinated (14) 
R97.26 R73.66 R115.00 R7.48 R462.15 R755.55 
NH: vaccinated (34) R42.41 R0.00 R118.38 R0.00 R66.20 R230.15 
 
A summary for the total cost of interventions, in Sandringham Gardens residents, 
based on table 4.6, is shown in table 4.7. 
 
Table 4.7: Summary for total cost of interventions - SG Residents, 
vaccinated and not vaccinated. 
 
Parameter Vaccinated Not Vaccinated 
Mean 328.16 319.75 
Number of points 24 61 
Std. deviation 495.30 667.91 
Std error 101.10 85.517 
Minimum 0.000 0.000 
Maximum 2011.0 4337.0 
Lower 95% CI 118.98 148.72 
Upper 95% CI 537.34 490.78 
 
Using an unpaired t test, the difference between the means of the cost of treating 
vaccinated Sandringham Gardens residents to non-vaccinated residents was not 
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significantly different. The two-tailed P value is 0.9556. The minimum cost in both 
groups is 0, as all subjects in the group were included. 
 
A summary for the total cost of interventions, in Sandringham Gardens ward 
subjects, based on table 4.6, is shown in table 4.8. 
 
Table 4.8: Summary for total cost of interventions - SG Ward subjects, 
vaccinated and not vaccinated. 
 
Parameter Vaccinated Not Vaccinated 
Mean 869.36 755.55 
Number of points 18 14 
Std. deviation 1173.5 1061.9 
Std error 276.61 283.81 
Minimum 0.000 0.000 
Maximum 4356.1 2972.9 
Lower 95% CI 285.72 142.53 
Upper 95% CI 1453.0 1368.6 
 
The difference between the means of the cost of treating vaccinated Sandringham 
Gardens wards subjects to non-vaccinated wards subjects was not significant. The 
two-tailed p value is 0.7787, t=0.2835 with 30 degrees of freedom (table 4.8). 
 
The difference between the mean cost of intervention in the Sandringham 
Gardens Residents who were vaccinated from the cost of intervention in the 
Nazareth House residents, all of whom were vaccinated was not significant. The 
two-tailed P value was 0.5237. 
 
The costs for the Sandringham Gardens ward subjects, in both the vaccinated and 
unvaccinated groups, were significantly higher than the healthier ambulatory 
subjects, in the residents subgroup. 
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CHAPTER 5 
Discussion 
 
5.1 Overview 
 
The aim of the study was to compare the costs of treating influenza and influenza-
like illnesses in old age home residents in Johannesburg, comparing people who 
had received the influenza vaccine with those who did not. The study took place at 
two sites, and over one season, namely April to October 2001. All the subjects 
were White. 
 
The literature supports the view that vaccination of the elderly, as well as old age 
home residents, both of whom are high risk groups for complications of influenza, 
is cost effective. In keeping with this, the South African guidelines recommend that 
old age home residents should have an annual influenza vaccination. Despite this, 
the vaccine is underutilised, and a number of reasons have been suggested for 
this. These include a lack of awareness both in doctors and in the general public of 
the benefits, as well as concerns about side effects in patients. 
 
Although serious side effects are rare, pain at the site of injection is common. 
Systemic flu-like effects are much less common in the general population, but are 
more common in the elderly.  
 
The subjects in this study who chose not to be vaccinated were asked to give a 
reason for their choice. A common answer was that the vaccine gave them “‘flu” in 
the past. This is not possible, as the vaccine described in this study were 
inactivated. Nevertheless, symptoms evoked by the vaccine may suggest to the 
patient that they have symptoms of ‘flu and it is very important to warn patients 
about this.  
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The effectiveness of the vaccine is queried by patients who develop other 
respiratory illnesses in winter, including more common upper respiratory tract 
infections following influenza vaccination. These other illnesses may be diagnosed 
as influenza by doctors, due to symptoms and signs being common to both.  
 
Most individuals who die from complications of influenza have underlying diseases 
that place them at high risk for complications of influenza. The most prominent 
high-risk conditions are chronic cardiac and pulmonary diseases. Mortality among 
individuals with chronic metabolic, renal, and certain immunosuppressive diseases 
has also been elevated, although lower than that among patients with chronic 
cardiopulmonary diseases. In this study, co-morbid conditions existed in all the 
subjects. 
 
The mean age of subjects in this study was 81.85 years. Although influenza 
vaccination is effective in the elderly, the mistaken belief that it is not effective in 
this age group may be one of the reasons for its underutilisation in old age home 
residents. In this study, 52 % of subjects were vaccinated for influenza. It would be 
expected that higher rates of vaccination would have provided herd immunity, and 
help protect the unvaccinated. 
 
This study did not show a significant cost saving in those ambulatory residents 
who were vaccinated. In the frail care subjects, there was a non-significant 
increase in costs. The limitations of this study which may explain these findings 
are discussed below. 
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5.2. Limitations of the Study 
 
5.2.1. Sample size  
 
The sample size was relatively small, and could have been increased by including 
other old age homes in the study.  
 
5.2.2. Seasonal variation in influenza morbidity 
 
The severity of influenza morbidity varies from season to season, and with a 
particularly severe influenza season, the benefits of vaccination may be more 
pronounced. Influenza during the 2001 winter season in South Africa was mild to 
moderate.27 Studies over a number of seasons are needed to assess the amount 
of bias created by this factor. Unfortunately there is no scientific and reliable way 
of forecasting beforehand whether the forthcoming winter will bring a mild or 
severe epidemic. 
 
5.2.3. Diagnosis of Influenza 
 
Clinical signs and symptoms were used in this study. A specific diagnosis can only 
be made definitively by isolating virus. Virological studies were not done for this 
study, as they are expensive, and funding was not available. Some studies have 
shown that cough and fever are the only factors significantly associated with a 
laboratory diagnosis of influenza.28, 29 An influenza-like illness can be caused by a 
variety of viral and nonviral pathogens, including influenza viruses, parainfluenza 
viruses, adenoviruses, respiratory syncytial virus, rhinovirus, Chlamydia 
pneumoniae and Mycoplasma pneumoniae. In the nursing home population, 
studies have shown that both influenza viruses and respiratory syncytial virus were 
associated with a flu-like illness and were among the leading causes of viral 
pneumonia. 28, 29 
 
 
33
One approach to this problem, used by other researchers was to assume that a 
specific percentage of all respiratory illness during the influenza season, for 
example 25 %, could be attributed to influenza. According to the World Health 
Organisation, during laboratory-confirmed influenza outbreaks, the majority of 
persons seeking medical advice for upper respiratory tract infections are likely to 
be infected by influenza. Some researchers used clinical indicators to make a 
diagnosis of influenza in old age home residents, but correlated this with 
virological evidence of a concurrent influenza epidemic in the general population. 5 
 
5.2.4. Use of over the counter medication  
 
Some ambulatory subjects may have used over the counter influenza medication 
to treat themselves, and this may cause an underestimation of costs. The findings 
in this study show that in most cases, the most expensive intervention was that of 
drug costs.  
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DOCTOR
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FIGURE 5.1: Relative costs of interventions. SG residents - not vaccinated 
 
 
5.2.5. Poor record keeping  
 
Accurate records of who received influenza vaccine were available for only 117 
subjects at Sandringham Gardens and only these were included in this study. 
Consent to participate in the study was obtained for 298 of the 340 residents at 
Sandringham Gardens. 
 
34
If a subject had died during the duration of the study, for any reason including 
influenza, the file was removed, and was not available for review. This problem 
could have been averted by reviewing the records on a monthly basis, instead at 
the end of the season. 
 
5.2.6. Population group studied 
 
The population group studied was limited to White subjects, with financial 
resources to afford a private old age home. It was planned to include two other 
sites, both old age homes in Alexandra. This was not done, as permission could 
not be obtained to do so. 
 
5.2.7. Cost of hospitalisation  
 
Only one subject was hospitalised, and as no details were available, these costs 
were not included. Subjects at Sandringham Gardens who needed treatment with 
intravenous antibiotics received this at the home. In other old age home settings, 
this may not have been possible, and the patient would have needed 
hospitalisation.  
 
5.2.8. Pneumococcal vaccination 
 
Records giving information on which subjects had received pneumococcal vaccine 
for the season studied or in previous years were not available. Previous records 
are relevant because the protection provided by the vaccine against 
pneumococcal infections lasts a number of years.  
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5.3. Relative costs of interventions 
 
A significant percentage of direct costs related to treatment of respiratory 
infections are for drugs. In the case of Sandringham Gardens residents who were 
not vaccinated, 63 % of total costs were for medication (figure 5.3, page 33). 
Antibiotics were the most expensive drugs prescribed. If a reliable and rapid 
diagnostic test for influenza was available, it may prevent the unnecessary use of 
antibiotics.  
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CHAPTER 6 
Conclusion 
 
This study measured the costs of treating influenza and influenza like illness in 
151 old age home residents in Johannesburg. The costs were compared between 
two groups, those who received influenza vaccine, and those who did not. The 
control group was made up of those who were not vaccinated, which was slightly 
over 50 % of the total. The costs of medical intervention were found to be similar in 
both groups of people in this study. There are a number of possible explanations 
for this, as described in the limitations of the study. Despite the findings of the 
study, influenza vaccination is still currently recommended for the elderly. 
 
Numerous studies have been published regarding cost evaluations of influenza 
vaccination in the United States of America, United Kingdom and other European 
countries. These studies conclude that in comparison with other health care 
interventions, influenza vaccination is one of the most cost-effective interventions 
possible in the older adult population, particularly those at higher risk, such as the 
elderly with chronic illness. In addition to cost benefits, there are also substantial 
health benefits to routine influenza vaccination. 
 
These findings have been implemented in the official guidelines of many countries, 
including the South African Adult influenza Vaccination Guideline. The findings of 
this study do not affect these local guidelines, due to the limitations which were 
described. Further studies in South Africa, including studies of old age homes 
where the residents are of lower socioeconomic groups, would be valuable. In this 
setting, it would be expected that less resources would be available for funding 
influenza vaccination.  
 
In order to increase influenza vaccination utilisation, medical practitioners need to 
be convinced of the benefits of annual influenza vaccination. Inaccurate beliefs 
about influenza vaccination persist in the community, and health care 
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professionals need to correct these misconceptions in order that those most at risk 
can benefit from influenza vaccination. 
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 APPENDIX A 
 
INFLUENZA SURVEY - INFORMATION LEAFLET AND INFORMED CONSENT 
2001 
Page 1 of 3 
 
Dear Resident 
 
We would like to invite you to participate in study concerning the use of the ‘flu 
vaccine (‘flu shots’) in residents of old age homes in Johannesburg. 
 
We would simply like to monitor the health of all residents in the home, both those 
who have the ‘flu vaccine and those who do not. We will not be changing anything 
whatsoever in the running of the home, or the administration of the ‘flu shots. 
 
If you do take part in the study, we would like to have access to your medical 
records for the duration of the study. (From April 2001 until the end of October 
2001). We would like you to report any episodes of illness during the duration of 
this study to the nursing staff who are responsible for your care. This is in addition 
to you seeing your usual doctor. 
 
Please note that the survey is completely anonymous and you cannot be identified 
in any way. Permission to carry out this study has been obtained from the 
Committee for Research on Human Subjects, of the University of the 
Witwatersrand. (“Ethics Committee”) 
 
Dr. Hugh Cobb is doing this study as part of the requirements for obtaining a 
Masters degree from the University of the Witwatersrand, together with the 
pharmaceutical company “Aventis Pasteur", who make a ‘flu vaccine’. 
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Page 2 of 3 
 
If you have any questions which are not fully explained in this leaflet, please 
contact Dr. Cobb for an explanation (Tel: 487-1714 or 082-344-5976). 
 
You do not have to take part in this study. If you change your mind at any time 
later you have the right to leave the study. If you choose to leave the study, it will 
not be detrimental to you in any way and you will still be treated to the best of the 
attending doctors’ ability.  
 
Your right as a Participant 
You have the right to privacy, and all information that is collected during this study 
is confidential. No study documentation that identifies you personally will ever be 
passed outside those directly involved in the study. Only the Ethics Committee will 
be granted direct access your records to verify study procedures or data. 
You do not have to take part in this study. If you change your mind at any time 
later you have the right to leave the study. If you choose to leave the study, it will 
not be detrimental to you in any way and you will still be treated to the best of the 
attending doctors’ ability. 
 
Informed Consent 
“I declare to have understood the objectives and the aim of the study, and to have 
obtained satisfactory answers to all of my questions. I have been informed that I 
can choose to withdraw my self from the study at any time, without affecting any 
future medical care to myself. I authorise Dr. H. Cobb, the Ethics Committee and 
Aventis Pasteur, to review my medical data. I am voluntarily participating in this 
study.” 
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Subject’s last and first names :  
……….............................................................. 
Inclusion number in the study :  
        |___|___|___|___|___| 
 
Date : _____/_____/_____ 
 
Signature*:  
 
Last and first name of a Witness: 
(unrelated to the investigator team if subject is 
unable to read and sign the form) 
..........................................................………….
 
Date : _____/_____/_____ 
 
Signature :  
 
Last and first name of individual obtaining 
consent :  
.......................................................……………
 
Date : _____/_____/_____ 
 
Signature : 
 
 
 
Thank you for your time and assistance. 
 
Dr. Hugh Cobb 
MB. B.Ch (Witwatersrand); DA (SA); DFM (Jer); MFGP (SA) 
35 Bedford Road 
Yeoville 
Johannesburg   Tel: 487-1714 
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APPENDIX B 
 
CASE REPORT FORM: COST ANALYSIS OF INFLUENZA VACCINE 
 
Subject inclusion number:  |__|__|__|__|__| 
Site:     Nazareth House  
      Sandringham Gardens  
Subject Initials:   |__|__|__| 
Gender:     F   M  
Date of Birth:    |__|__| |__|__| |__|__|__|__| 
        d      d        m    m        y     y      y      y 
 
Informed consent obtained: YES  NO  
If yes, Date of informed consent: |__|__| |__|__| |__|__|__|__| 
        d      d        m    m        y     y      y      y 
 
1. Vaccination History: 
Yes Vaccine 
received Yes If Yes, what 
date received 
Commercial name of 
vaccine received 
No 
Influenza     
Pneumococcal     
Other (specify)     
Other (specify)     
 
 
2. Review of Contraindication to Influenza Vaccine 
Contraindication Yes No 
Anaphylactic hypersensitivity to eggs   
Allergy to other components of the vaccine   
Acute severe febrile illness   
No informed consent   
Other reason (besides below)   
Subject chooses not to be vaccinated. 
If possible, state reason. 
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3. Review of Medical History from Records 
 Date of review:   |__|__| |__|__| |__|__|__|__| 
        d      d        m    m        y     y      y      y 
 
 Presence or absence of condition Yes No 
1. Emphysema / Chronic Obstructive Airway Disease   
2. Asthma   
3. Diabetes Mellitus (Insulin Dependent)   
4. Diabetes Mellitus (Non Insulin Dependent)   
5. Congestive Heart Failure   
6. Hypertension   
7. Previous Pneumonia   
8. Previous vaccination with pneumococcal vaccine   
9. Neurological disease 
       Type: (eg. Parkinson’s disease)   
 
 
3 Monthly record review of symptoms during the past month 
Syptom April May June July Aug Sep Oct Nov Dec 
Date of record review 
(dd/mm/yy)                   
 Y N Y N Y N Y N Y N Y N Y N Y N Y N 
Malaise                   
Cough                    
Rhinorrhoea                   
Sore throat                   
Chills                   
Headache                   
Anorexia                   
Myalgia                   
Productive cough                   
Dizziness                   
Hoarseness                   
Chest pain                   
Vomiting                   
Diarrhoea                   
Abdominal pain                   
Diagnosis 
 E.g. URTI / FLU / LRTI / 
       Pneumonia 
  April         May        June          July          Aug         Sept         Oct          Nov         Dec 
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3. Record review of interventions 
 Apr May Jun Jul Aug Sep Oct Nov Dec 
Date of record 
review (dd/mm/yy)          
INTERVENTION Y N Y N Y N Y N Y N Y N Y N Y N Y N 
Doctor Consultation                   
Referral to hospital 
(please complete 
hospitalisation 
section if 
hospitalised) 
                  
FBC                   
Other blood tests 
(please specify)                   
Chest x-ray                   
Antibiotics (please 
give dose and 
duration) 
                  
Symptomatic 
medication (please 
specify under 
medications section) 
                  
Chest physiotherapy                   
Nebulisations 
(please specify 
under medications 
section 
                  
 
6. Record of medications 
Drug 
Name Indication Dosage Route 
Date 
started 
Duration 
of 
treatment 
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7. Hospitalisation 
Reason for 
Hospitalisation 
Name of 
Hospital 
Special 
transport 
required 
(e.g. 
ambulance) 
Y / N 
Date 
admitted 
Date 
discharged 
ICU 
required 
(Y / N) 
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